Study Summary
Alzheimer’s disease is a progressive condition that affects memory, thinking, and daily function. While many people associate Alzheimer’s with memory loss, the disease is more complex than that. Researchers believe inflammation, changes in brain structure, vascular health, and communication between brain cells may all play a role in how the disease develops and progresses.
Because of this, scientists are continuing to explore new approaches that may help support brain health in different ways. One area of interest is mesenchymal stem cell therapy, also known as MSC therapy.
This study looked at an investigational MSC therapy called laromestrocel, also known as Lomecel-B, in people with mild Alzheimer’s disease. Laromestrocel is made from allogeneic mesenchymal stem cells, meaning the cells come from healthy adult donors rather than from the patient receiving the treatment.
The goal of the study was mainly to evaluate safety; while also looking for early signs of how the therapy might affect memory, daily function, inflammation, and brain volume.
Why Researchers Studied This
MSCs are being studied in regenerative medicine because they release signals that may help regulate inflammation, support tissue repair, and influence immune activity. In Alzheimer’s disease, inflammation in the brain is believed to be one factor that may contribute to ongoing damage.
Rather than directly replacing brain cells, MSCs may work more through cell signaling. This means they may help create a healthier environment around existing cells by releasing helpful molecules that influence inflammation, blood vessel health, and repair-related pathways.
For a condition like Alzheimer’s, which involves several overlapping biological changes, this type of approach is especially interesting to researchers.
How the Study Was Designed
This was a phase 2a clinical trial that included 49 people with mild Alzheimer’s disease across 10 clinical centers in the United States. The study was randomized, double-blind, and placebo-controlled, meaning neither the participants nor the study team knew who received the therapy or placebo during the trial.
Participants were divided into groups that received either placebo or different dosing schedules of laromestrocel. Some received one infusion, while others received four monthly infusions at different doses.
Researchers followed participants for 39 weeks and looked at several outcomes, including:
- Safety and side effects
- Cognitive testing
- Daily living function
- Brain imaging
- Signs related to inflammation and brain volume changes
Main Findings
The study met its main safety goal. Serious adverse events within the first 4 weeks after infusion were similar between the placebo group and the treatment groups. The researchers also reported no infusion-related reactions, no hypersensitivity reactions, and no amyloid-related imaging abnormalities.
The study also found some encouraging early signals in people who received laromestrocel. Compared with placebo, treated participants showed improvement on a combined Alzheimer’s disease assessment score at 39 weeks. The study also reported positive changes in measures related to cognition and daily function.
Brain imaging results were also interesting. Participants who received laromestrocel showed slower progression of whole brain volume loss compared with placebo. The study also reported slower decline in the left hippocampus, an area of the brain that is closely connected to memory and is often affected in Alzheimer’s disease.
The researchers also observed imaging signs that may suggest reduced neuroinflammation. This is notable because inflammation in the brain is becoming an important area of Alzheimer’s research.
What This Could Mean
This study does not mean MSC therapy is a cure for Alzheimer’s disease. However, it does suggest that laromestrocel may be worth studying further.
The findings are interesting because they point to a therapy that may work differently from many traditional Alzheimer’s treatments. Instead of focusing on just one target, MSC therapy may influence several biological processes at once, including inflammation, vascular support, and tissue repair signaling.
This broader approach may be important because Alzheimer’s disease is not caused by one single factor. It involves many changes in the brain over time.
Important Limitations
Although the results are promising, this was still an early-stage study with a small number of participants. The follow-up period was also relatively short for a condition like Alzheimer’s disease, which progresses over many years.
Larger studies are needed to better understand how safe and effective laromestrocel may be over time. Future research will also need to explore the best dose, how long results may last, and which patients may be most likely to benefit.
Conclusion
This study provides an interesting look at how mesenchymal stem cell therapy may be studied for mild Alzheimer’s disease. Laromestrocel was generally well tolerated in this phase 2a trial, and the researchers observed early signs of benefit in cognition, daily function, brain volume changes, and inflammation-related imaging.
While more research is needed before strong conclusions can be made, the study adds to the growing interest in regenerative medicine approaches for neurological conditions. It also highlights the potential of therapies that focus on supporting the brain environment, regulating inflammation, and protecting function over time.
Source
Rash BG, Ramdas KN, Agafonova N, Naioti E, McClain-Moss L, Zainul Z, Varnado B, Peterson K, Brown M, Leal T, Kopcho S, Carballosa R, Patel P, Brody M, Fuquay A, Rodriguez S, Jacobson AF, Leon R, Pfeffer M, Schwartzbard JB, Botbyl J, Oliva AA Jr, Hare JM, et al. Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: a randomized controlled phase 2a trial. Nature Medicine. 2025 Apr;31:1257–1266. doi: 10.1038/s41591-025-03559-0. PMID: 40065171; PMCID: PMC12003194. Available from: https://www.nature.com/articles/s41591-025-03559-0
Related Treatment Pages